Skip to main content
Fig. 3 | Journal of Hematology & Oncology

Fig. 3

From: Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells

Fig. 3

GLPG1790 induces G1 growth arrest and related cell cycle protein modulation. a FACS analysis performed on ERMS cells untreated (DMSO) or treated with 3.5 μM GLPG1790 for 24 h. Representative of three different experiments (upper panel). Histograms showing the percentage of cell cycle phases in RD and TE671 cells ± GLPG1790 (lower panel). Results represent the mean value of four independent experiments. b Cell lysates from RD and TE671 cells ± GLPG1790 at the indicated times were analysed by immunoblotting with specific antibodies for indicated proteins; α-Tubulin expression shows the loading of samples. Representative of three independent experiments. c Immunofluorescence experiments showing the expression and localization of CycD1 and p21 at 72 h after DMSO (−) or GLPG1790 (+) treatment. Representative images captured under ApoTome microscope at 40x magnification

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us